Who's 'Afrezza' the FDA? Not MannKind, Still Plugging Away

As FDA-mandated Phase III trials near their finish with MannKind Corp.'s beleaguered inhaled insulin product Afrezza, Alfred Mann, CEO and major funder of the company, took to the lectern at the J.P. Morgan Healthcare Conference to deliver a familiar message: It works, the device is simple and patients will use it.